Consensus Alvotech Nyse

Equities

Market Closed - Nyse Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
13.37 ^USD	-1.69%		-6.27%	+42.54%

04-30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
04-30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

bd1f8b.ZaKX_jjmq4H-j_dFA2PuAXMZreBLG54hGdXe3eNfEwM.JNDwuk6j4NOvw5UnYgiUVSlY3KoxVtdkbKWUrbsZJGZI_eaZXp7y5bS_xw~cd9db50d9aff1ec01e6c9411f5f1b20d

Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	03-22	MT
Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	01-29	MT
Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	23-10-20	MT
Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	23-09-21	MT
Deutsche Bank Adjusts Alvotech Price Target to $8 From $12, Maintains Hold Rating	23-06-30	MT
Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating	23-03-07	MT
Morgan Stanley Starts Alvotech at Equalweight With $10 Price Target	22-09-07	MT
Citigroup Double Downgrades Alvotech to Sell From Buy, Adjusts Price Target to $5 From $12	22-09-06	MT
Citigroup Starts Alvotech at Buy With $12 Price Target	22-07-26	MT
Deutsche Bank Initiates Coverage on Alvotech With Hold Rating, $10 Price Target	22-07-01	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.6 USD

Average target price

16.5 USD

Spread / Average Target

+21.32%

High Price Target

28 USD

Spread / Highest target

+105.88%

Low Price Target

6 USD

Spread / Lowest Target

-55.88%

Trading Rating

Investor Rating

ESG Refinitiv